Department of Veterans Affairs (2025) Ozempic, DailyMed (2025) Step therapys balancing actprotecting patients while addressing high drug prices, New England Journal of Medicine (2023) Semaglutide (Wegovy) subcutaneous injection for weight management: Criteria for use, VA Pharmacy Benefits Management Services and National Formulary Committee (2025) VA priority groups, VA.gov (2024) Current VA health care copay rates, VA.gov (2025) VA tier 1 copay medication list, VA.gov (2025) State overviews, Medicaid.gov (n.d.) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
In March 2025, Roche entered an exclusive collaboration and licensing agreement with Zealand Pharma to co-develop and co-commercialise Zealand Pharmas amylin analogue, petrelintide, as a therapy for obesity in combination with Roches dual GLP-1/GIP receptor agonist, CT-388 9
[4] This triple-action approach is designed to offer more benefits than single-receptor therapies (like semaglutide) or dual-receptor therapies (like tirzepatide)
In clinical trials, about 40% of people (women, in the HSDD trials) experienced nausea after a dose of bremelanotide
Benefits Skin Brightening Skin Elasticity Youthful Skin Skin Hydration
(2024) reported that neither semaglutide nor the dual GIP/GLP-1 agonist tirzepatide influenced disease-related pathology, behavior, or cognitive function in 5XFAD and APP/PS1 mouse models of Alzheimers disease when administered after the establishment of pathology (Forny Germano et al., 2024)